Glucotrack, Inc. Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Institutional Investor

Core Viewpoint - Glucotrack, Inc. has entered into a securities purchase agreement with an institutional investor to raise approximately $4.0 million through the sale of common stock and warrants, aimed at supporting its operations and development of diabetes-related technologies [1][2]. Group 1: Securities Offering - The company will sell 1,033,591 shares of common stock and warrants to purchase up to 2,067,182 shares at an effective combined price of $3.87 per share, resulting in gross proceeds of about $4.0 million before expenses [1]. - The closing of the offering is anticipated to occur on or about December 31, 2025, pending customary closing conditions [2]. - The warrants will have an exercise price of $3.87 per share, will require shareholder approval before being exercisable, and will expire five years from the initial exercise date [1]. Group 2: Use of Proceeds - The net proceeds from the offering are expected to be utilized for working capital and general corporate purposes [2]. Group 3: Company Overview - Glucotrack, Inc. focuses on the design, development, and commercialization of innovative technologies for diabetes management [5]. - The company is developing a long-term implantable continuous blood glucose monitoring system, which features a sensor longevity of three years and minimal calibration requirements [6].